Pharma firms pursue microgravity cancer drug development in orbit

Pharmaceutical companies are increasingly using microgravity environments on orbital platforms to improve cancer drug crystallization and formulation, a trend that has been building over recent years. The article highlights the potential of space-based R&D to yield more effective treatments, though commercial viability and regulatory pathways remain uncertain. This signals a growing intersection of space infrastructure and biotech innovation.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works